Here's why the Vanguard Utilities ETF (NYSEMKT: VPU), Vanguard Consumer Staples ETF (NYSEMKT: VDC), and Vanguard Health Care ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its ... the company said in the statement. Its health care ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by cost-cutting measures and ...

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a ...

Markets are also analyzed by application. One of Europe's most significant strategic assets is the life science industry, which produces cutting-edge drugs and vaccines essential to the long-term ...